348 related articles for article (PubMed ID: 30639533)
1. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Hsiao SH; Lusvarghi S; Huang YH; Ambudkar SV; Hsu SC; Wu CP
Cancer Lett; 2019 Mar; 445():34-44. PubMed ID: 30639533
[TBL] [Abstract][Full Text] [Related]
2. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
3. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.
Hsiao SH; Murakami M; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV; Wu CP
Cancer Lett; 2018 Oct; 434():81-90. PubMed ID: 30031116
[TBL] [Abstract][Full Text] [Related]
4. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
5. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
6. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Hung TH; Lusvarghi S; Chu YH; Hsiao SH; Huang YH; Chang YT; Ambudkar SV
Biochem Pharmacol; 2021 Jun; 188():114516. PubMed ID: 33713643
[TBL] [Abstract][Full Text] [Related]
7. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
8. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.
Gupta P; Gao HL; Ashar YV; Karadkhelkar NM; Yoganathan S; Chen ZS
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641875
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro.
Hsiao SH; Lu YJ; Li YQ; Huang YH; Hsieh CH; Wu CP
Mol Pharm; 2016 Jun; 13(6):2117-25. PubMed ID: 27169328
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
13. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.
Sucha S; Sorf A; Svoren M; Vagiannis D; Ahmed F; Visek B; Ceckova M
Biomed Pharmacother; 2022 Jun; 150():112962. PubMed ID: 35462331
[TBL] [Abstract][Full Text] [Related]
16. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.
Liao D; Zhang W; Gupta P; Lei ZN; Wang JQ; Cai CY; Vera AA; Zhang L; Chen ZS; Yang DH
Molecules; 2019 Nov; 24(23):. PubMed ID: 31801248
[TBL] [Abstract][Full Text] [Related]
18. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
Wang J; Yang DH; Yang Y; Wang JQ; Cai CY; Lei ZN; Teng QX; Wu ZX; Zhao L; Chen ZS
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092870
[TBL] [Abstract][Full Text] [Related]
20. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
Wang YJ; Kathawala RJ; Zhang YK; Patel A; Kumar P; Shukla S; Fung KL; Ambudkar SV; Talele TT; Chen ZS
Biochem Pharmacol; 2014 Aug; 90(4):367-78. PubMed ID: 24937702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
